Skip to main content

Table 4 Relations between pre-ER and Pathological Response in Tumor Site

From: Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months

  DFS OS
Variables No.(%) Log-Rank P No.(%) Log-Rank P
Before surgery     
   Age     
≤ 50 30(41.7%)   36(41.4%)  
>50 42(58.3%) 0.792 51(58.6%) 0.638
   Clinial stage     
II B 20(27.8%)   23(26.4%)  
III A 34(47.2%)   39(44.9%)  
III B 14(19.4%)   18(20.7%)  
III C 4(5.6%) 0.517 7(8.0%) 0.195
   cALN     
negative 21(29.2%)   25(28.7%)  
positive 51(70.8%) 0.522 62(71.3%) 0.295
   ER     
negative 33(45.8%)   37(42.5%)  
positive 39(54.2%) 0.580 50(57.5%) 0.045
   PR     
negative 32(44.4%)   38(43.7%)  
positive 40(55.6%) 0.155 49(56.3%) 0.026
   HER-2     
0-2+ 52(72.2%)   63(72.4%)  
3+ 20(27.8%) 0.778 24(27.6%) 0.643
   Ki67     
≤ 20% 49(68.1%)   58(66.7%)  
>20% 23(31.9%) 0.071 29(34.3%) 0.055
   Pathology     
IDC 57(79.1%)   69(79.3%)  
ILC 2(2.8%)   2(2.3%)  
other 13(18.1%) 0.987 16(18.4%) 0.934
   Clinical response     
CR 20(27.8%)   11((12.6%)  
PR 44(61.1%)   54(62.2%)  
SD 7(9.7%)   21(24.1%)  
PD 1(1.4%) 0.284 1(1.1%) 0.651
After surgery     
   cALN     
negative 49(68.1%)   60(69.0%)  
positive 23(31.9%) 0.848 27(31.0%) 0.912
   ER※     
negative 55(76.4%)   67(77.0%)  
positive 17(23.6%) 0.965 20(23.0%) 0.827
   PR※     
negative 54(75.0%)   67(77.0%)  
positive 18(25.0%) 0.428 20(23.0%) 0.864
   HER-2※     
0-2+ 50(69.4%)   60(69.0%)  
3+ 22(30.6%) 0.568 27(31.0%) 0.328
   Ki67※     
≤ 20% 66(91.7%)   80(92.0%)  
>20% 6(8.3%) 0.025 7(8.0%) 0.001
   pALN     
N 0 23(31.9%)   27(31.0%)  
N 1-3 18(25.0%)   20(23.0%)  
N 4-9 18(25.0%)   23(26.5%)  
N >9 13(18.1%) 0.456 17(19.5%) 0.425
   Pathological tumor size    
≤ 2 cm 14(19.4%)   18(20.7%)  
> 2 cm 41(56.9%)   48(55.2%)  
unmeasured 17(23.7%) 0.256 21(24.1%) 0.303
   Grade     
I 1(1.4%)   1(1.2%)  
II 39(54.2%)   47(54.0%)  
III 8(11.1%)   11(12.6%)  
Not graded 24(33.3%) 0.624 28(32.2%) 0.827
   pathological response in tumor site    
pCR 21(29.2%)   22(25.3%)  
non-pCR 51(70.8%) <0.001 65(74.7%) 0.003
  1. Abbreviations: DFS, disease free survival, OS, overall survival; OR, odds ratio; 95%CI, 95% confidence interval; cALN, clinical axillary lymph node; pALN: pathological axillary lymph node; IDC: Invasive ductal cancer; ILC: Invasive lobular cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; pCR, pathological complete response.
  2. ※109 patients were evaluated after neoadjuvant chemotherapy, because of 10 patients with no residual tumor in postoperative tissue.
  3. *115 Patients were evaluable for survival (4 patients were lost to follow-up)